DK3675894T3 - Sammensætning til kontrolleret ovariestimulation - Google Patents

Sammensætning til kontrolleret ovariestimulation Download PDF

Info

Publication number
DK3675894T3
DK3675894T3 DK18768795.9T DK18768795T DK3675894T3 DK 3675894 T3 DK3675894 T3 DK 3675894T3 DK 18768795 T DK18768795 T DK 18768795T DK 3675894 T3 DK3675894 T3 DK 3675894T3
Authority
DK
Denmark
Prior art keywords
ovarium
stimulation
composition
controlled
ovarium stimulation
Prior art date
Application number
DK18768795.9T
Other languages
Danish (da)
English (en)
Inventor
Saez Joan-Carles Arce
Lisbeth Helmgaard
Bjarke Mirner Klein
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of DK3675894T3 publication Critical patent/DK3675894T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18768795.9T 2017-09-01 2018-08-31 Sammensætning til kontrolleret ovariestimulation DK3675894T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (en) 2017-09-01 2018-08-31 COMPOSITION FOR CONTROLLED OVARIAN STIMULATION

Publications (1)

Publication Number Publication Date
DK3675894T3 true DK3675894T3 (da) 2022-01-24

Family

ID=59772482

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18768795.9T DK3675894T3 (da) 2017-09-01 2018-08-31 Sammensætning til kontrolleret ovariestimulation
DK21196378.0T DK3973982T3 (da) 2017-09-01 2018-08-31 Sammensætning til kontrolleret ovariestimulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK21196378.0T DK3973982T3 (da) 2017-09-01 2018-08-31 Sammensætning til kontrolleret ovariestimulation

Country Status (32)

Country Link
US (2) US11744879B2 (enExample)
EP (3) EP3973982B1 (enExample)
JP (2) JP6856819B2 (enExample)
KR (2) KR20250078595A (enExample)
CN (2) CN120617484A (enExample)
AR (1) AR112541A1 (enExample)
AU (1) AU2018326556B2 (enExample)
BR (1) BR112020003379A2 (enExample)
CA (1) CA3073624A1 (enExample)
CL (1) CL2020000482A1 (enExample)
DK (2) DK3675894T3 (enExample)
EA (1) EA202090480A1 (enExample)
ES (2) ES2904787T3 (enExample)
FI (1) FI3973982T3 (enExample)
HR (2) HRP20211802T1 (enExample)
HU (2) HUE068024T2 (enExample)
IL (1) IL272763B2 (enExample)
JO (1) JOP20200034A1 (enExample)
LT (2) LT3973982T (enExample)
MA (2) MA50034B1 (enExample)
MD (2) MD3973982T2 (enExample)
MX (2) MX2020002235A (enExample)
MY (1) MY200791A (enExample)
PH (1) PH12020500404A1 (enExample)
PL (2) PL3973982T3 (enExample)
PT (2) PT3675894T (enExample)
RS (2) RS62810B1 (enExample)
SG (1) SG11202003840QA (enExample)
SI (2) SI3973982T1 (enExample)
TW (1) TWI749255B (enExample)
UA (1) UA126869C2 (enExample)
WO (1) WO2019043143A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267608T1 (de) * 2000-01-27 2004-06-15 Applied Research Systems Verwendung von fsh zur behandlung von infertilität
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
CA2700335C (en) * 2007-09-21 2015-12-01 Pharmabrand S.A. Composition comprising mucilaginous polysaccharides derived from aloe barbadensis combined with liposomes, method for obtaining same and use thereof as a sun protector, an anti-acne agent, an epidermal regenerator and a moisturiser
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
WO2011089602A2 (en) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
CA2945883A1 (en) * 2014-04-18 2015-10-22 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone
MD3261661T2 (ro) 2015-02-26 2024-04-30 Ferring Bv Menotropină pentru tratarea infertilității
HUE048757T2 (hu) * 2015-04-17 2020-08-28 Ferring Bv FSH meddõség kezelésére
EP3286209B1 (en) 2015-04-24 2020-11-25 Ferring BV Method of production of gonadotrophin
AU2016282916B2 (en) 2015-06-26 2022-01-20 Ferring B.V. Methods of purification and/or viral inactivation
PL3787667T3 (pl) 2018-04-30 2025-07-28 Ferring B.V. Kompozycja do kontrolowanej stymulacji jajników
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
US20240024424A1 (en) 2024-01-25
IL272763B2 (en) 2024-02-01
CN111050787A (zh) 2020-04-21
PL3973982T3 (pl) 2024-11-04
AR112541A1 (es) 2019-11-06
EA202090480A1 (ru) 2020-07-20
IL272763B1 (en) 2023-10-01
EP4427806A2 (en) 2024-09-11
SG11202003840QA (en) 2020-05-28
RS65945B1 (sr) 2024-10-31
UA126869C2 (uk) 2023-02-15
FI3973982T3 (fi) 2024-09-23
CN120617484A (zh) 2025-09-12
JP2021046398A (ja) 2021-03-25
KR20250078595A (ko) 2025-06-02
HRP20211802T1 (hr) 2022-03-04
HUE056726T2 (hu) 2022-03-28
DK3973982T3 (da) 2024-09-23
HUE068024T2 (hu) 2024-12-28
SI3973982T1 (sl) 2024-10-30
MA56224B1 (fr) 2024-09-30
MX2024009224A (es) 2024-08-06
PT3675894T (pt) 2022-01-25
MA50034B1 (fr) 2022-02-28
PT3973982T (pt) 2024-09-16
MA50034A (fr) 2021-05-12
LT3973982T (lt) 2024-09-10
BR112020003379A2 (pt) 2020-08-25
SI3675894T1 (sl) 2022-01-31
EP4427806A3 (en) 2024-10-09
IL272763A (en) 2020-04-30
ES2989511T3 (es) 2024-11-26
TWI749255B (zh) 2021-12-11
CL2020000482A1 (es) 2020-06-26
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
EP3973982A1 (en) 2022-03-30
US20200197493A1 (en) 2020-06-25
US11744879B2 (en) 2023-09-05
EP3973982B1 (en) 2024-07-31
WO2019043143A1 (en) 2019-03-07
MY200791A (en) 2024-01-16
JP2020528071A (ja) 2020-09-17
MD3973982T2 (ro) 2024-11-30
AU2018326556A1 (en) 2020-03-05
MX2020002235A (es) 2020-07-20
AU2018326556B2 (en) 2024-09-26
TW201919687A (zh) 2019-06-01
PH12020500404A1 (en) 2021-03-01
MA56224A (fr) 2022-04-20
JP7373479B2 (ja) 2023-11-02
ES2904787T3 (es) 2022-04-06
KR20200045543A (ko) 2020-05-04
EP3675894B1 (en) 2021-11-03
EP3675894A1 (en) 2020-07-08
MD3675894T2 (ro) 2022-03-31
CA3073624A1 (en) 2019-03-07
JOP20200034A1 (ar) 2020-02-13
HRP20241171T1 (hr) 2024-11-22
RS62810B1 (sr) 2022-02-28
JP6856819B2 (ja) 2021-04-14

Similar Documents

Publication Publication Date Title
EP3722358A4 (en) COMPOSITION
DK3697376T3 (da) Sammensætning
EP3493800A4 (en) CANNABIS
DK3119808T3 (da) Antistofsammensætninger til tumorbehandling
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
EP3514627A4 (en) PHOTO POLYMER COMPOSITION
DK3528902T3 (da) Ringegelsammensætning
EP3590548A4 (en) COMPOSITION FOR SKIN INJECTION
DK3787667T3 (da) Sammensætning til kontrolleret ovariestimulation
EP3812426A4 (en) CURABLE COMPOSITION
EP3480228A4 (en) COMPOSITION
EP3590546A4 (en) COMPOSITION FOR SKIN INJECTION
EP3530711A4 (en) GEL COMPOSITION
EP3443034C0 (en) COMPOSITION
DK3416502T3 (da) Glykæmisk-reducerende sammensætning
EP3675653C0 (fr) Composition antimycotoxine
DK3675894T3 (da) Sammensætning til kontrolleret ovariestimulation
EP3524627A4 (en) COMPOSITION
EP3521505A4 (en) Composition
PL3481406T3 (pl) Kompozycja
DK3349752T3 (da) Aza-adamantan sammensætning til sårheling
EP3388089A4 (en) PEPTIDE COMPOSITION
EP3782632A4 (en) ANTISTRESS COMPOSITION
ES1209313Y (es) Composicion liofilizada
DK3294682T3 (da) Sammensætning til overfladebehandling